Spesolimab use in treatment of pyoderma gangrenosum
Authors:
Open Access
- 4 February 2023
- journal article
- research article
- Published by Elsevier in JAAD Case Reports
- Vol. 34, 18-22
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Trial of Spesolimab for Generalized Pustular PsoriasisNew England Journal of Medicine, 2021
- Prevalence estimates for pyoderma gangrenosum in the United States: An age- and sex-adjusted population analysisJournal of the American Academy of Dermatology, 2020
- Biology of IL-36 Signaling and Its Role in Systemic Inflammatory DiseasesFrontiers in Immunology, 2019
- Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and TreatmentAmerican Journal of Clinical Dermatology, 2017
- Neutrophil-Derived Proteases Escalate Inflammation through Activation of IL-36 Family CytokinesCell Reports, 2016
- Canakinumab in adults with steroid‐refractory pyoderma gangrenosumBritish Journal of Dermatology, 2015
- Inter-Regulation of Th17 Cytokines and the IL-36 Cytokines In Vitro and In Vivo: Implications in Psoriasis PathogenesisJournal of Investigative Dermatology, 2011
- Adalimumab for treatment of pyoderma gangrenosumBritish Journal of Dermatology, 2007
- Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trialGut, 2005
- Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody.2001